Anixa Biosciences, Inc. (NASDAQ:ANIX) Short Interest Up 13.7% in January

Anixa Biosciences, Inc. (NASDAQ:ANIX) was the target of a significant growth in short interest in January. As of January 31st, there was short interest totalling 403,100 shares, a growth of 13.7% from the January 15th total of 354,500 shares. Based on an average daily trading volume, of 121,000 shares, the days-to-cover ratio is presently 3.3 days. Approximately 1.3% of the shares of the stock are sold short.

Analyst Upgrades and Downgrades

A number of brokerages have recently issued reports on ANIX. HC Wainwright reaffirmed a “buy” rating and issued a $7.00 price target on shares of Anixa Biosciences in a research note on Tuesday, November 19th. D. Boral Capital reissued a “buy” rating and set a $10.00 price objective on shares of Anixa Biosciences in a research note on Wednesday, January 22nd.

Anixa Biosciences Stock Performance

NASDAQ ANIX opened at $3.14 on Monday. The stock’s fifty day moving average is $2.70 and its two-hundred day moving average is $3.05. The firm has a market capitalization of $101.10 million, a P/E ratio of -8.05 and a beta of 0.93. Anixa Biosciences has a fifty-two week low of $2.07 and a fifty-two week high of $4.35.

Anixa Biosciences (NASDAQ:ANIX) last released its quarterly earnings data on Friday, January 10th. The company reported ($0.09) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.11) by $0.02. As a group, sell-side analysts forecast that Anixa Biosciences will post -0.46 EPS for the current year.

Insider Activity

In other news, Director Lewis H. Titterton, Jr. purchased 10,000 shares of the stock in a transaction dated Friday, January 17th. The shares were purchased at an average cost of $2.57 per share, with a total value of $25,700.00. Following the completion of the purchase, the director now directly owns 922,334 shares of the company’s stock, valued at approximately $2,370,398.38. The trade was a 1.10 % increase in their position. The transaction was disclosed in a document filed with the SEC, which is available through this link. Also, CEO Amit Kumar purchased 43,000 shares of the stock in a transaction dated Wednesday, January 15th. The stock was purchased at an average cost of $2.23 per share, for a total transaction of $95,890.00. Following the completion of the purchase, the chief executive officer now directly owns 559,925 shares of the company’s stock, valued at approximately $1,248,632.75. The trade was a 8.32 % increase in their ownership of the stock. The disclosure for this purchase can be found here. Insiders acquired 75,289 shares of company stock worth $177,021 over the last three months. 25.30% of the stock is currently owned by corporate insiders.

Institutional Investors Weigh In On Anixa Biosciences

A number of institutional investors and hedge funds have recently added to or reduced their stakes in the business. Renaissance Technologies LLC raised its position in Anixa Biosciences by 36.5% in the fourth quarter. Renaissance Technologies LLC now owns 14,573 shares of the company’s stock valued at $34,000 after purchasing an additional 3,900 shares during the period. Virtu Financial LLC purchased a new stake in Anixa Biosciences in the third quarter valued at $34,000. LPL Financial LLC raised its position in Anixa Biosciences by 37.2% in the fourth quarter. LPL Financial LLC now owns 42,937 shares of the company’s stock valued at $100,000 after purchasing an additional 11,633 shares during the period. Tyler Stone Wealth Management raised its position in Anixa Biosciences by 100.0% in the third quarter. Tyler Stone Wealth Management now owns 42,016 shares of the company’s stock valued at $132,000 after purchasing an additional 21,008 shares during the period. Finally, Westside Investment Management Inc. raised its position in Anixa Biosciences by 151.8% in the third quarter. Westside Investment Management Inc. now owns 35,000 shares of the company’s stock valued at $110,000 after purchasing an additional 21,100 shares during the period. Hedge funds and other institutional investors own 29.13% of the company’s stock.

About Anixa Biosciences

Anixa Biosciences, Inc, a biotechnology company, develops therapies and vaccines focusing on critical unmet needs in oncology and infectious diseases. The company's therapeutics programs include the development of a chimeric endocrine receptor T-cell therapy, a novel form of chimeric antigen receptor T-cell (CAR-T) technology focusing on the treatment of ovarian cancer.